Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the ...

CureVac N.V. (NASDAQ:CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained by over 16% in the past month, with a major surge following the June 12 announcement that the ...

On June 12, 2025, BioNTech SE (“BioNTech”) announced its entry into a definitive purchase agreement to acquire all shares of CureVac N.V. (“CureVac”), with an implied aggregate equity ...

Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% ...

CureVac N.V. (NASDAQ:CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained by over 16% in the past month, with a major surge following the June 12 announcement that the ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in an all-stock transaction. As part of the deal, CureVac investors will ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of ...

While BioNTech boasts ~$13bn cash thanks to its Comirnaty windfall, CureVac does not have anything like the same funding, with an accumulated deficit of ~$1.73bn, hence it is hardly surprising the ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised ...